Xenon Pharmaceuticals Inc.
XENE
$35.32
$0.140.40%
| Weiss Ratings | XENE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | XENE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | XENE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.62 | |||
| Price History | XENE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.98% | |||
| 30-Day Total Return | -12.73% | |||
| 60-Day Total Return | -11.81% | |||
| 90-Day Total Return | -14.08% | |||
| Year to Date Total Return | -12.07% | |||
| 1-Year Total Return | -19.12% | |||
| 2-Year Total Return | 2.41% | |||
| 3-Year Total Return | 27.10% | |||
| 5-Year Total Return | 227.34% | |||
| 52-Week High % Change | -23.52% | |||
| 52-Week Low % Change | 5.74% | |||
| Price | XENE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $46.00 | |||
| 52-Week Low Price | $33.27 | |||
| 52-Week Low Price (Date) | Feb 28, 2025 | |||
| 52-Week High Price (Date) | Nov 08, 2024 | |||
| Valuation | XENE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.69B | |||
| Enterprise Value | 1.95B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.01 | |||
| Earnings Per Share Growth | 10.19% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 3.56 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $35.32 | |||
| Enterprise Value/EBITDA (TTM) | -7.04 | |||
| Enterprise Value/EBIT | -6.97 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | XENE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 78.39M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | XENE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 604 484 3300 | |||
| Address | 3650 Gilmore Way Burnaby, BC V5G 4W8 | |||
| Website | www.xenon-pharma.com | |||
| Country | Canada | |||
| Year Founded | 1996 | |||
| Profitability | XENE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | XENE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -19.80% | |||
| Return on Equity | -- | |||
| Income Statement | XENE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -210.39M | |||
| EBITDA (TTM) | -276.74M | |||
| EBIT (TTM) | -279.30M | |||
| Net Income (TTM) | -234.33M | |||
| Net Income Avl. to Common (TTM) | -234.33M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -46.81% | |||
| EPS Diluted (TTM) | -3.01 | |||
| EPS Diluted Growth (Q YOY) | -31.04% | |||
| Balance Sheet | XENE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 626.91M | |||
| Cash Per Share (Q) | $8.00 | |||
| Total Current Assets (Q) | 635.26M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 754.90M | |||
| Current Ratio (Q) | 17.850 | |||
| Book Value Per Share (Q) | $9.88 | |||
| Total Assets (Q) | 798.14M | |||
| Total Current Liabilities (Q) | 35.59M | |||
| Total Debt (Q) | 9.02M | |||
| Total Liabilities (Q) | 43.24M | |||
| Total Common Equity (Q) | 754.90M | |||
| Cash Flow | XENE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 165.00M | |||
| Cash from Financing (TTM) | 12.13M | |||
| Net Change in Cash (TTM) | -5.93M | |||
| Levered Free Cash Flow (TTM) | -145.31M | |||
| Cash from Operations (TTM) | -181.39M | |||
